Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Last trade$944.12
Day change-$6.83 (-0.72%)
Day range$921.35 – $953.05
Volume292,116
Market cap$59.80B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ARGX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ARGX.
Recent news
Company coverage with links to the original publishers.
Halozyme Therapeutics (HALO) has surged 43.1% over six months, outperforming the industry and S&P 500, driven by strong royalty revenues from its ENHANZE drug delivery technology partnerships. The company raised 2026 guidance with total revenues expected to reach $1.86-$1.925 billion and royalty revenues of $1.24-$1.26 billion. While recent acquisitions and proprietary product growth support long-term prospects, heavy reliance on partner companies for royalty income remains a key risk. Zacks rates the stock as a Hold.
The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.
AstraZeneca received FDA and EU regulatory approvals for Klygefa (gefurulimab), a complement C5 inhibitor for treating adults with AChR-positive generalized myasthenia gravis. The once-weekly, self-administered subcutaneous therapy showed significant improvements in daily activities versus placebo in Phase III trials. While the convenient dosing offers differentiation from AstraZeneca's existing IV therapies (Soliris and Ultomiris), Klygefa faces cannibalization risks and competition from other complement C5 inhibitors and alternative mechanism drugs.
Halozyme Therapeutics raised its 2026 revenue guidance to $1.86-$1.925 billion (33-38% YoY growth) and royalty revenue guidance to $1.24-$1.26 billion (42-45% YoY growth), driven by increased royalties from partnered drugs including J&J's Darzalex, argenx's Vyvgart Hytrulo, and Roche's Phesgo. The company's stock has rallied 53% year-to-date, though it trades at a premium valuation compared to the industry.
Pomerantz LLP is investigating argenx SE for potential securities fraud following the company's announcement on October 8, 2026, that it will discontinue its Phase 3 UNITY study of efgartigimod for Sjögren's disease due to futility. The stock price fell 11.83% ($109.81 per share) to $818.63 on the news.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.